文献速递慢性肾脏病肾血管病与高血压

老年慢性肾脏病合并心房颤动患者抗凝治疗与缺血性卒中及出血的关联

The association of anticoagulation, ischemic stroke, and hemorrhage in elderly adults with chronic kidney disease and atrial fibrillation.
PubMed 文献 · Kidney Int · 2016-12-22

这项基于人群的回顾性队列研究纳入6544例66岁及以上、估算肾小球滤过率低于45 ml/min/1.73m²的慢性肾脏病合并新发心房颤动患者,其中1475例开具抗凝药处方。经倾向性评分匹配后分析1417对患者,抗凝治疗与缺血性卒中风险降低无关,但与出血风险升高及死亡风险降低相关。

要点

  • 在老年晚期慢性肾脏病合并心房颤动患者中,抗凝治疗与缺血性卒中风险降低无关。
  • 抗凝治疗与出血风险升高相关,且竞争风险分析后结果一致。
  • 抗凝治疗与死亡风险降低相关。

核心结论

  • 在老年慢性肾脏病合并心房颤动患者中,开具抗凝药处方与缺血性卒中风险降低无关,但与出血风险升高和死亡风险降低相关。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入6544例66岁及以上、估算肾小球滤过率低于45 ml/min/1.73m²的慢性肾脏病合并新发心房颤动患者,其中1475例开具抗凝药处方。
  • 采用倾向性评分匹配的Cox比例风险模型和竞争风险模型分析至首次缺血性卒中、出血或死亡事件的时间,匹配后得到1417对患者。

主要发现

  • 匹配后,抗凝治疗组与非抗凝治疗组的缺血性卒中粗发生率分别为每100人年41.3和34.4,出血粗发生率分别为每100人年61.3和34.3。
  • 与未开具抗凝药处方相比,开具抗凝药处方的缺血性卒中风险比为1.10(95%置信区间0.78-1.56),出血风险比为1.42(95%置信区间1.04-1.93),死亡风险比为0.74(95%置信区间0.62-0.88)。
  • 考虑死亡的竞争风险后,缺血性卒中和出血的风险比分别为1.12(95%置信区间0.90-1.39)和1.60(95%置信区间1.31-1.97)。
  • 考虑时变抗凝暴露的敏感性分析结果一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The utility of anticoagulants for ischemic stroke prophylaxis in elderly patients with chronic kidney disease (CKD) and atrial fibrillation remains uncertain. In this population-based retrospective cohort study, we determined the association of anticoagulant use with ischemic stroke or hemorrhage in elderly patients (66 years and older) with advanced chronic kidney disease (eGFR under 45 ml/min/1.73m2) and atrial fibrillation. We followed 6,544 patients with CKD and new onset atrial fibrillation, of whom 1,475 filled a prescription for an anticoagulant. We used propensity-score matched Cox proportional hazards and competing risk models to determine the time to first event of ischemic stroke, hemorrhage or mortality. After matching to examine exposure to anticoagulants, 1,417 matched pairs were identified. The crude rate of ischemic stroke and hemorrhage were 41.3 and 61.3 with anticoagulants and 34.4 and 34.3 without anticoagulants per 100 person-years, respectively. The hazard ratios of ischemic stroke, hemorrhage, and mortality for receipt of an anticoagulation prescription were 1.10 (95% confidence interval, 0.78-1.56), 1.42 (1.04-1.93), and 0.74 (0.62-0.88) as compared to non-receipt of anticoagulation. After accounting for the competing risk of death, the hazard ratios for ischemic stroke and hemorrhage were 1.12 (0.90-1.39) and 1.60 (1.31-1.97), respectively. The findings were consistent in a sensitivity analysis accounting for time varying anticoagulant exposure. Thus, in older patients with CKD and atrial fibrillation, receipt of an anticoagulant was not associated with a lower risk of ischemic stroke, but a higher risk of hemorrhage and a lower risk of mortality.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Keskar V, McArthur E, Wald R, et al. The association of anticoagulation, ischemic stroke, and hemorrhage in elderly adults with chronic kidney disease and atrial fibrillation. Kidney Int. 2016. PMID: 28017326. doi:10.1016/j.kint.2016.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。